Australia Health

BCAL Diagnostics (ASX:BDX) has developed a diagnostic blood test that achieved 91% sensitivity for detecting breast cancer recurrence.

Neurizon Therapeutics (ASX:NUZ) executed an agreement with Elanco Animal Health (NYSE:ELAN) to secure a five-year supply of human-health monepantel.

Island Pharmaceuticals (ASX:ILA) secured US FDA Orphan Drug Designation for Galidesivir.

Racura Oncology (ASX:RAC) has raised $34.3 million to fully fund three upcoming clinical trials.

Dimerix (ASX:DXB) executed a licensing agreement with Everest Medicines to develop and commercialise its clinical-stage drug candidate, DMX-200.

Sigma Healthcare (ASX:SIG) has walked away from preliminary discussions to acquire UK health and beauty retailer Boots.

Echo IQ (ASX:EIQ) announced a research collaboration with Mayo Clinic to evaluate its proprietary artificial intelligence platform.

Neurizon Therapeutics (ASX:NUZ) announced that its HEALEY ALS Platform Trial has surpassed the critical 50% dosing milestone.

Monash IVF Group (ASX:MVF) revised its financial outlook for 2026, forecasting an underlying net profit after tax of between $17 million and $18 million.

Prescient Therapeutics (ASX:PTX) announced the appointment of Dr Rosalind Wilson as its new Chief Medical Officer, effective July 13.

Australian mental health prescriptions surge as nearly one in five citizens are prescribed psychiatric medications.

Island Pharmaceuticals (ASX:ILA) expands US Army partnership to advance a critical Galidesivir dose optimisation study.